drugset / Trial / NCT06955390

Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors

NCT06955390

Phase 1/2 Not yet recruiting 32 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of HRS-4642 combined with SHR-A2102 in the treatment of advanced solid tumors

Timeline

Start
2025-05-01
Primary completion
2025-12-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-4642 Unknown
Subject SHR-A2102 Other / unclassified

Indications